Long-term use of the psoriasis medication etanercept does not cause more infections or adverse events than placebo, research has shown.
The drug also made improvements in Psoriasis Area and Severity Index (PASI) over the course of the 96-week trial.
First, 618 psoriasis patients were given either a placebo or 50 milligrams of etanercept for 12 weeks. Then all 591 continuing patients received etanercept for 84 weeks.
PASI scores peaked at week 48 and at the end of the study, 51.6% of the trial's original etanercept group's scores improved by at least 75%, compared with 51.1% of placebo.
Archives of Dermatology (2007) 143:710-726